AngioDynamics, Inc. - Common Stock (ANGO)
11.74
+0.67 (6.05%)
NASDAQ · Last Trade: Oct 2nd, 10:06 PM EDT
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&P 500 also rose, gaining, 0.07% to 6,715.87.
Via Benzinga · October 2, 2025
Even 37 years after its founding, AngioDynamics still can't earn a profit.
Via The Motley Fool · October 2, 2025
Shares of AngioDynamics, Inc. (NASDAQ: ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.
Via Benzinga · October 2, 2025
Via Benzinga · October 2, 2025
AngioDynamics (ANGO) beat Q1 FY2026 earnings and revenue estimates, driven by strong Med Tech growth. The company also raised its full-year financial outlook.
Via Chartmill · October 2, 2025
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.
Via Benzinga · October 2, 2025
CNN Business Fear & Greed Index at 52.3, remaining in Neutral zone. Stocks close higher despite economic headwinds, with record S&P 500 level.
Via Benzinga · October 2, 2025
US stock futures mixed, with attention on earnings reports from companies like AngioDynamics, Grindr, and Entero Therapeutics.
Via Benzinga · October 2, 2025
Via Benzinga · October 1, 2025
Via Benzinga · August 7, 2025
Via Benzinga · July 28, 2025
AngioDynamics' big Q4 earnings beat wasn't as impressive as it first seemed.
Via The Motley Fool · July 15, 2025
AngioDynamics expects a $4 million-$6 million impact from tariffs. Still, it's "profitable," CEO Jim Clemmer says.
Via Benzinga · July 15, 2025
Via Benzinga · July 14, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · July 14, 2025
Via Benzinga · April 2, 2025
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · April 2, 2025
AngioDynamics raised its fiscal 2025 sales outlook to $285M-$288M and boosted its adjusted EBITDA forecast, expecting stronger Med Tech revenue growth.
Via Benzinga · April 2, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · April 2, 2025